TrivarX Ltd. engages in clinical research, product development, and early-stage commercialization of mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.
Follow-Up Questions
MDBIF の株価パフォーマンスは？
MDBIF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
TrivarX Ltd の主な事業テーマや業界は？
TrivarX Ltd は Health Care 業界、セクターは Health Care に属しています。
